REFERENCES

1. A.B. Baranda, N. Etxebarria, R.M. Jimenez, et al. (2005); Development of a liquid–liquid extraction procedure for five 1,4-dihydropyridines calcium channel antagonists from human plasma using experimental design; Talanta, 67, pp. 933–941.
2. Arnaout S (2015); Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study; Curr Med Res Opin.; 31(1):page: 187-90.
3. Australian pesticides and veterinary medicines authority (2004), Guidelines for the validation of analytical methods for active constituents, agricultural and veterinary chemical products.
4. B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng (2003); Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS; Anal. Chem., 75, pp. 3019–3030.
5. B.K. Matuszewski (2006); Standard line slopes as a measure of a relative matrix effect in quantitative HPLC–MS bioanalysis; J. Chromatogr. B, 830, pp. 293–300.
6. Bjoern B. Burckhardt and Stephanie Laeer (2015); Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat; International Journal of Analytical Chemistry; Article ID 796249, 11 pages.
7. Burckhardt BB, Tins J, Laeer S. (2014); Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. Biomed Chromatogr.;28(12): page: 1679-91.
8. C.A. Mueller, A.B. Gonzalez, W. Weinmann (2004); Screening for dihydropyridine calcium channel blockers in plasma by automated solid-phase extraction and liquid chromatography/tandem mass spectrometry; J. Mass Spectrom., 39, pp. 639–646.

9. C. Borghi (2005); Lercanidipine in hypertension Vasc. Health Risk Manag., 1, pp. 173–182
10. C. Borghi and F. Santi (2012); Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence Patient Preference Adherence, 6, pp. 449–455.
11. C. N. Kang, H. J. Kim, Y. S. Park, S. H. Kim, H. K. Park, H. S. Hwang and J. S. Kang (2014): A simple and rapid LC-MS/MS method for the determination of Enalapril in human plasma for pharmacokinetic and bioequivalence studies in korean healthy volunteers under fasting conditions; J. Anal. Chem.; 69 (5): page: 467-473.
12. Cheregi M, Albu F, Udrescu Ș, Răducanu N, Medvedovici A. (2013);; Greener bioanalytical approach for LC/MS-MS assay of enalapril and enalaprilat in human plasma with total replacement of acetonitrile throughout all analytical stages. J Chromatogr B Analyt Technol Biomed Life Sci. 927; page:124-132.
13. Danafar H and Hamidi M. (2015); Liquid chromatography-tandem mass spectrometry (LC-MS) method for the assignment of enalapril and enalaprilat in human plasma; Pharm Biomed Res; 1 (3); page: 47– 58.
14. Darshan V. Chaudhary, Daxesh P. Patel, Priyanka A. Shah, Jaivik V. Shah, Mallika Sanyal and Pranav S. Shrivastav (2016); Determination of lercanidipine in human plasma by an improved UPLC–MS/MS method for a bioequivalence study; Journal of Pharmaceutical Analysis, 6(2), Pages 87–94.
15. Dr. M. Sunitha Reddy, Navya Sai.K, S. Muhammad Fazal Ul Haq (2015); Method development and validation of UV spectroscopic method for the determination of lercanidipine; World journal of Pharmaceutical Research, 4 (10); page: 1341-1348.
16. F. Ozturk, I.H. Tasdemir, D.A. Erdogan, et al. (2011); A new voltammetric method for the determination of lercanidipine in biological samples; Acta Chim. Slov., 58, pp. 830–839.
17. Ghosh C, Jha V, Ahir R, Shah S, Shinde CP, Chakraborty BS. (2010); A rapid and most sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of alverine and its major metabolite, para hydroxy

alverine, in human plasma: application to a pharmacokinetic and bioequivalence study.Drug Test Anal.: page: 284-291.

18. Ghosh C, Jain I, Shinde CP, Chakraborty BS (2012); Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. Drug Test Anal.; 4(2): page: 94-103.
19. Grassi G (2016); Lercanidipine/enalapril combination in the management of obesity-related hypertension. Integr Blood Press Control.;9; page:69-77.
20. Guidance for Industry (1996): ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER).
21. Guidance for Industry (2001), Bionanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM).
22. Gu Q, Chen X, Zhong D, Wang Y. (2004); Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci.;813(1-2):page: 337-342.
23. H. O. Kaila, M. A. Ambasana, R. S. Thakkar, H. T. Saravaia, and A. K. Shah (2011); A Stability-indicating High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Atenolol and Lercanidipine Hydrochloride in Tablets; Indian J Pharm Sci.; 73(4): 376–380.
24. Hossein danafar and Mehrdad hamidi (2016); A quick and superficial liquid chromatography–tandem mass spectrometry (LC-MS) method for the determination of enalapril and enalaprilat in human plasma: Application to a Bioequivalence Study. Iranian Journal of Pharmaceutical Sciences; 10 (4), page: 21-34.
25. I.I. Salem, J. Idrees, J.I. Al Tamimi, et al. (2004); Selective and rapid liquid chromatography mass spectrometry method for the determination of lercanidipine in human plasma; J. Chromatogr. B, 803, pp. 201–207.

26. Jaeick Lee, Junghyun Son, Mijin Lee, Kyung Tae Lee and Dong-Hyun Kim (2003); Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry; Rapid Comm. in Mass Spec.; 17 (11); page: 1157-1162.
27. João Maldonado, Telmo Pereira and Alfredo Tavares (2014); Efficacy and Safety of a Lercanidipine/Enalapril Fixed-Dose Combination in Hypertensive Patients in Portugal; Drugs R D.; 14 (2); page: 147 – 154.
28. K. Chen, J. Zhang, S. Liu, et al. (2012); Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC–MS/MS and its application to a toxicokinetics study; J. Chromatogr. B, 899, pp. 1–7.
29. K. Makwana, R. Dhamecha and N. Pandya (2013); Bioanalytical Method Validation for the Determination of Enalapril in Human Serum by Lc/Ms/Ms Detection; Paripex-Indian journal of Research; 2 (3); page: 296-298.
30. Kareem M. Younes and Ehab F. El Kady (2013); A new validated bio-analytical liquid chromatographic -tandem mass spectrometric method for the quantification of Lercanidipine in human plasma; International Journal of Analytical and Bioanalytical chemistry, 3(4); page: 169–177.
31. Kyung-Hwan Yoon, Won Kim, Jongsei Park and Hie-Joon Kim (2004); Determination of Enalapril in Human Plasma by High Performance Liquid Chromatography – Electrospray Ionization Mass Spectrometry; Bull Korean Chem Soc. 25; page: 878-880.
32. L.M. Bang, T.M. Chapman, K.L. Goa (2003); Lercanidipine: A Review of its efficacy in the management of hypertension; Drugs, 63, pp. 2449–2472.
33. Lee J, Son J, Lee M, Lee KT, Kim DH. (2003); Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom.;17(11): page: 1157-1162.
34. Lima DM, Mundim IM, Jardim PC, Jardim TS, Diniz DG, Lima EM. (2009); A high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method using solid phase extraction for the simultaneous determination of plasma concentrations of enalapril and enalaprilate in hypertensive patients

treated with different pharmaceutical formulations. Ther Drug Monit.;31(6):page: 710-716.

35. Lu S, Jiang K, Qin F, Lu X, Li F. (2009); Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal.;49(1): page:163-167.
36. M. Barchielli, E. Dolfini, E., P. Farina, et al. (1997); Clinical pharmacokinetics of lercanidipine; J. Cardiovasc. Pharmacol., 29 (Suppl. 2), pp. S1–S15
37. M.T. Pruijm, M.P. Maillard, M. Burnier (2008); Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine Vasc. Health Risk Manag., 4, pp. 1159–1166.
38. M. Kalovidouris, S. Michalea, N. Robola, et al. (2006); Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma; Rapid Commun. Mass Spectrom., 20, pp. 2939–2946.
39. Nilesh Jain, Ruchi Jain, Navneet Thakur, Surendra Jain and Deepak Kumar Jain (2011); Simultaneous Spectrophotometric Estimation of Lercanidipine Hydrochloride and Atenolol in Tablet Dosage Form; Eurasian Journal of Analytical Chemistry, 6(2); 84-90.
40. O. Gonzalez, R.M. Alonso, N. Ferreirós, et al. (2011); Development of an LC–MS/MS method for the quantitation of 55 compounds prescribed in combined cardiovascular therapy; J. Chromatogr. B, 879, pp. 243–252.
41. P.I. Hair, L.J. Scott, C.M. Perry (2007); Fixed-dose combination lercanidipine/enalapril Drugs, 67, pp. 95–106.
42. R. Fogari, A. Mugellini, A. Zoppi (2003); Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am. J. Hypertens., 16, pp. 596–599.
43. Ramusovic S, Thielking G, Läer S. (2012); Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Biomed Chromatogr.; 26(6): page: 697-702.

44. S. Charde, L. Kumar, R. Saha (2007); Development and validation of high-performance liquid chromatographic method for estimation of lercanidipine in rabbit serum; Anal. Lett., 40, pp. 2128–2140.
45. Shan Lu, Kun Jiang, Feng Qin, Xiumei Lu and Famei Li (2009); Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study Journal of pharmaceutical and biomedical analysis; 49(1); page:163-167.
46. Tajerzadeh H and Hamidi M. (2001); A simple HPLC method for quantitation of enalaprilat. J Pharm Biomed Anal 24(4); page: 675-680.
47. V.A.P. Jabor, E.B. Coelho, D.R. Ifa, et al. (2003); Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography–tandem mass spectrometry; J. Chromatogr. B, 796, pp. 429–437
48. V.A.P. Jabor, E.B. Coelho, V.L. Lanchote (2004); Enantioselective pharmacokinetics of lercanidipine in healthy volunteers; J. Chromatogr. B, 813, pp. 343–346.
49. Y. Altun, B. Uslu, S.A. Ozkan (2010); Electroanalytical characterization of lercanidipine and its voltammetric determination in pharmaceuticals and human serum on boron-doped diamond electrode; Anal. Lett., 43, pp. 1958–1975.